REGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM

NEWS RELEASE - REGULATED INFORMATION

27 OCTOBER 2022, 4:00PM EDT / 22:00 CET

MDxHealth Reports Q3-2022 Results

IRVINE, CA, and HERSTAL, BELGIUM -

October 27, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics

company, today announced its financial results for the third quarter ended September 30, 2022.

Michael K. McGarrity, CEO of mdxhealth, commented:

"We are pleased to report continued strong operating results for the third quarter 2022. Our focus on operating discipline and commercial

execution and continued implementation of our growth strategy is building the foundation for sustained growth for mdxhealth as the leading

provider of personalized diagnostic solutions focused exclusively into urology."

for the third quarter ended September 30, 2022

of Billable Test Volume by Product

review for the three and nine months ended September 30, 2022

Total revenue for the three months ended September

30, 2022, was $11.2 million, an increase of 103% as compared to total revenue of $5.5 million for the three months ended September 30,

2021. Excluding the Oncotype DX GPS revenues, total revenues for the quarter were $7.8 million, an increase of 42% compared to the third

For the nine months ended September 30, 2022,

total revenue was $24.2 million, an increase of 49% as compared to total revenue of $16.2 million for the nine months ended September

30, 2021. Excluding the Oncotype DX GPS revenues, total revenues were $20.8 million, an increase of 28% compared to the first nine months

Gross profit for the three months ended September

30, 2022, was $6.2 million, an increase of 143% as compared to $2.6 million for the three months ended September 30, 2021. Gross margins

were 55.8% for Q3-2022 as compared to 46.6% for Q3-2021, an improvement of 917 basis points attributed to contribution from Resolve mdx

and the addition of initial Oncotype DX GPS revenues.

For the nine months ended September 30, 2022,

gross profit was $12.0 million, an increase of 54% as compared to $7.8 million for the first nine months of 2021. Gross margins were 49.6%

for the first nine months of 2022 as compared to 47.9% for the first nine months of 2021.

Operating expenses for the three months ended

September 30, 2022, were $14.4 million, up 48% from $9.7 million for the three months ended September 30, 2021, primarily driven by acquisition-related

expenses as well as additional field sales personnel associated with the Oncotype DX GPS business.

For the nine months ended September 30, 2022,

operating expenses were $37.2 million, up 36% from $27.4 million for the nine months ended September 30, 2021, primarily due to additional

public company expenses as a result of the dual listing as well as expenses related to the acquisition of the Oncotype DX GPS business

Operating loss and net loss for the three months

ended September 30, 2022, were $8.1 million and $8.6 million, respectively, compared to $7.1 million and $7.6 million, respectively, for

the three months ended September 30, 2021.

For the nine months ended September 30, 2022,

operating loss and net loss were $25.2 million and $26.7 million, respectively, compared to $19.6 million and $20.9 million, respectively,

for the nine months ended September 30, 2021.

Cash and cash equivalents as of September 30,

2022, were $27.4 million.

Mr. McGarrity concluded, "Today's

results reflect our previously communicated view that mdxhealth is fast becoming a leading precision diagnostics company that can deliver

sustainable growth. We anticipate coverage for our Select mdx test, coupled with the addition of our UTI and GPS test revenue, will further

support gross margin accretion. While we are still at the beginning stages of our integration plan for the Oncotype DX GPS business, our

field sales organization is now fully restructured and in place to support our growth, and we look forward to providing a view forward

of 2023 as we enter the new year."

Mdxhealth is a commercial-stage precision diagnostics

company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based

on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis

of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California,

with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen,

and linkedin.com/company/mdxhealth.

For more information:

This press release contains forward-looking

statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements

and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed

reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's

control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make

regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations

for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those

indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19)

pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully and profitably

market our products; the acceptance of our products and services by healthcare providers; the willingness of health insurance companies

and other payers to cover our products and services and adequately reimburse us for such products and services; and the amount and nature

of competition for our products and services. MDxHealth expressly disclaims any obligation to update any such forward-looking statements

in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on

which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation

for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within

the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,

and in accordance with any applicable U.S. securities laws.

NOTE: The mdxhealth logo, mdxhealth,

Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth

SA. All other trademarks and service marks are the property of their respective owners.

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the three months ended September 30, 2022

For the nine months ended September 30, 2022